Release Date: November 07, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you provide more details on the commercial launch of KOSTAIVE in Japan and expectations for the winter season going into 2025? A: Andrew Sassine, CFO, explained that Meiji, the number one flu vaccine company in Japan, plans to sell approximately 4.5 million vaccines this season. The initial shipment of 4 million doses has been made, and the remaining vaccines will be produced domestically by ARCALIS once approved. The full launch is expected by December, with more updates to come from Meiji and CSL.
Q: What can you share about the Phase 2 cystic fibrosis study, including size, cohorts, and proof of concept requirements? A: Padmanabh Chivukula, COO and CSO, mentioned that the study will evaluate multiple doses and measure FEV1 throughout. The study is open-label, without bronchoscopy, and aims to recruit participants who do not respond to CFTR modulators. More details will be shared early next year.
Q: Regarding the OTC deficiency study, why was the interim data readout shifted to the first half of next year? A: Joseph Payne, CEO, stated that the US expansion is similar in size to the European study. The decision to combine data from both regions for a comprehensive interim update in the first half of 2025 was made to provide a more complete analysis.
Q: Can you elaborate on the revenue recognition process for KOSTAIVE sales in Japan? A: Andrew Sassine, CFO, explained that Meiji will report sales to CSL, which will then allocate profit shares among CSL, Meiji, and Arcturus. Revenue recognition will occur once allocations are made, considering the 40% production cost offset. Initial revenues are expected in the first half of 2025.
Q: What differentiates ARCT-032 from competitors like Vertex/Moderna's VX-522 in the cystic fibrosis space? A: Joseph Payne, CEO, highlighted that ARCT-032 uses a unique Lunar delivery technology, which is biodegradable and non-accumulating. Preclinical data shows significant responses, and the purification process of mRNA is a key differentiator, ensuring high purity for chronic dosing in compromised lungs.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.